Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Grant Funding
  • Pipeline
  • News & Media
    • Press Releases
    • Events
    • Publications
    • In the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • Publications
  • In the News

Navidea Biopharmaceuticals to Host Fourth Quarter 2020 Earnings Conference Call and Corporate Update

Mar 17, 2021

Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

Mar 2, 2021

Navidea Biopharmaceuticals Announces $5 Million Private Placement with Existing Investor

Mar 2, 2021

Navidea Biopharmaceuticals Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis

Feb 8, 2021

Navidea Biopharmaceuticals to Present at the 2021 ICR Conference On January 14, 2021

Jan 7, 2021

Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter

Dec 28, 2020

Navidea Biopharmaceuticals Reports Third Quarter and Year-to-Date 2020 Financial Results

Nov 12, 2020

Navidea Biopharmaceuticals Announces Positive Results Encompassing Additional Patients From Its Ongoing Phase 2B Study in Rheumatoid Arthritis

Nov 12, 2020

Navidea Biopharmaceuticals to Host Third Quarter 2020 Earnings Conference Call and Corporate Update

Nov 5, 2020

Navidea Biopharmaceuticals to Present at the Virtual Investor KOL Roundtable

Oct 22, 2020
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...43
    © 2023 Navidea Biopharmaceuticals, Inc. All Rights Reserved.
    linkedin
    Privacy Policy Disclaimer Sitemap